160 related articles for article (PubMed ID: 28626987)
21. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
22. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
23. Pituitary tumour apoplexy within prolactinomas in children: a more aggressive condition?
Culpin E; Crank M; Igra M; Connolly DJA; Dimitri P; Mirza S; Sinha S
Pituitary; 2018 Oct; 21(5):474-479. PubMed ID: 30014342
[TBL] [Abstract][Full Text] [Related]
24. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
25. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of multimodal therapy for giant prolactinomas.
Andujar-Plata P; Villar-Taibo R; Ballesteros-Pomar MD; Vidal-Casariego A; Pérez-Corral B; Cabezas-Agrícola JM; Álvarez-Vázquez P; Serramito R; Bernabeu I
Endocrine; 2017 Jan; 55(1):231-238. PubMed ID: 27704480
[TBL] [Abstract][Full Text] [Related]
27. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
28. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome.
Iglesias P; Bernal C; Villabona C; Castro JC; Arrieta F; Díez JJ
Clin Endocrinol (Oxf); 2012 Aug; 77(2):281-7. PubMed ID: 22288612
[TBL] [Abstract][Full Text] [Related]
29. Influence of age on the clinical presentation of prolactinomas in male patients.
Delgrange E; Maiter D; Donckier J; Tourniaire J
Gerontology; 1999; 45(3):160-4. PubMed ID: 10202261
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
31. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
32. Management of cystic prolactinomas: a review.
Nakhleh A; Shehadeh N; Hochberg I; Zloczower M; Zolotov S; Taher R; Daoud Naccache D
Pituitary; 2018 Aug; 21(4):425-430. PubMed ID: 29654440
[TBL] [Abstract][Full Text] [Related]
33. Macroprolactinomas: retrospective follow up study in the MR imaging and correlation with clinical symptomatology.
Vaneckova M; Seidl Z; Hana V; Jarkovska Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):841-5. PubMed ID: 18063932
[TBL] [Abstract][Full Text] [Related]
34. Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.
Arya VB; Aylwin SJB; Hulse T; Ajzensztejn M; Kalitsi J; Kalogirou N; Bodi I; Thomas N; Hampton T; Kapoor RR; Buchanan CR
Clin Endocrinol (Oxf); 2021 Mar; 94(3):413-423. PubMed ID: 33340135
[TBL] [Abstract][Full Text] [Related]
35. Management of prolactinomas during pregnancy.
Witek P; Zieliński G
Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
[TBL] [Abstract][Full Text] [Related]
36. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
37. Prolactinoma-associated headache and dopamine agonist treatment.
Kallestrup MM; Kasch H; Østerby T; Nielsen E; Jensen TS; Jørgensen JO
Cephalalgia; 2014 Jun; 34(7):493-502. PubMed ID: 24351278
[TBL] [Abstract][Full Text] [Related]
38. Macroprolactinoma: a diagnostic and therapeutic update.
Iglesias P; Díez JJ
QJM; 2013 Jun; 106(6):495-504. PubMed ID: 23329574
[TBL] [Abstract][Full Text] [Related]
39. Clinical Features and Response to Treatment of Prolactinomas in Children and Adolescents: A Retrospective Single-Centre Analysis and Review of the Literature.
Breil T; Lorz C; Choukair D; Mittnacht J; Inta I; Klose D; Jesser J; Schulze E; Bettendorf M
Horm Res Paediatr; 2018; 89(3):157-165. PubMed ID: 29455199
[TBL] [Abstract][Full Text] [Related]
40. Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years.
Shimon I; Hirsch D; Tsvetov G; Robenshtok E; Akirov A; Fraenkel M; Eizenberg Y; Herzberg D; Barzilay-Yoseph L; Livner A; Friedrich I; Manisterski Y; Ishay A; Yoel U; Masri H
Endocrine; 2019 Sep; 65(3):656-661. PubMed ID: 31154607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
